Fig. 1.

High expression of FBXO22 increases sensitivity to IR and cisplatin. (A) FBXO22 was overexpressed in EBC-1 cells (FBX). Controls were cells with empty vector (Vec). (B) The cells were exposed to IR (2, 5, or 10 Gy) or kept untreated. Seven days after exposure, the cells were lysed and the A₂₆₀ was measured as an indication of the total amount of nucleic acid. The fraction of surviving cells was calculated relative to untreated cells. (C) Cells were treated with cisplatin and the survival was determined after 72 h. The fraction of surviving cells was calculated relative to vehicle controls. (D) FBXO22 was overexpressed in A549 cells. Cell survival was measured after treatment with IR (E) or cisplatin (F). (G) FBXO22 was overexpressed in Calu1 cells. Cell survival was measured after treatment with IR (H) or cisplatin (I). (J) The level of FBXO22 was analyzed in FBXO22 knockout (KO) A549 cells. The cells were exposed to IR, and their viability was determined 7 d later (K). Each cell survival assay was performed at least three times, and the data shown represent means ± SD of three experiments, in which each measurement was performed in triplicate. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.